Comparative Pharmacology
Head-to-head clinical analysis: ADVIL ALLERGY SINUS versus DICLOFENAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL ALLERGY SINUS versus DICLOFENAC.
ADVIL ALLERGY SINUS vs DICLOFENAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.
Diclofenac inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.
Oral: 50 mg twice daily or 75 mg twice daily; maximum 150 mg/day. Topical: apply 4 times daily. IM: 75 mg once daily.
None Documented
None Documented
Clinical Note
moderateDiclofenac + Gatifloxacin
"Diclofenac may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateDiclofenac + Rosoxacin
"Diclofenac may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateDiclofenac + Levofloxacin
"Diclofenac may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateDiclofenac + Trovafloxacin
"Diclofenac may increase the neuroexcitatory activities of Trovafloxacin."
2–4 hours (pseudoephedrine: 5–8 hours); clinical context: requires q4-6h dosing for pain/fever, q6-8h for congestion
Terminal elimination half-life ~2 h (diclofenac immediate-release); enterohepatic recirculation may produce secondary peaks. Clinical context: Short half-life requires multiple daily dosing for sustained effect.
Renal (90% as conjugates and metabolites; <10% unchanged); biliary/fecal (<5%)
Renal (65% as metabolites, <1% unchanged); biliary/fecal (35% as metabolites).
Category C
Category D/X
NSAID/Decongestant/Antihistamine Combination
NSAID